Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study-Reference-Cited by-同舟云学术

Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study

Published:2014-11-06 Issue:11 Volume:9 Page:e112201
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Krens Lisanne L.,Simkens Lieke H. J.,Baas Jara M.,Koomen Els R.,Gelderblom Hans,Punt Cornelis J. A.,Guchelaar Henk-Jan

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference21 articles.

1. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials;DA Eisenberg;Am J Med,1998

2. Statin use and reduced cancer-related mortality;SF Nielsen;N Engl J Med,2012

3. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets;PA Konstantinopoulos;Nat Rev Drug Discov,2007

4. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review;J Tol;Clin Ther,2010

5. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer;A Lievre;Cancer Res,2006

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of metformin and statin uses with the prognosis of colon cancer: a meta-analysis;European Journal of Cancer Prevention;2024-01-15

2. Role of non-canonical post-translational modifications in gastrointestinal tumors;Cancer Cell International;2023-09-30

3. Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy;Cancer Cell International;2023-04-17

4. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation;Theranostics;2023

5. Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs;Biochemical Pharmacology;2022-02